Back to Search
Start Over
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial.
- Source :
-
Annals of Oncology . Jan2022, Vol. 33 Issue 1, p114-116. 3p. - Publication Year :
- 2022
- Subjects :
- *HEPATOCELLULAR carcinoma
*ATEZOLIZUMAB
*SORAFENIB
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 154895206
- Full Text :
- https://doi.org/10.1016/j.annonc.2021.10.008